Aleddra Smart Disinfection and Emergency Lighting Ideal for Healthcare Facilities
RENTON, Wash., Nov. 2, 2022 /PRNewswire/ -- The healthcare engineers and facilities managers are always overloaded with work and looking for products that will meet and exceed their standards. " When they learned that Aleddra ' s smart emergency Gen4 T8 tube automatically performs the monthly and the annual audit tests, they couldn ' t wait to test/approve the Gen4 for their facilities, " according to Matthew Maa, VP Sales& Marketing. The Gen4 Emergency T8 tube is recognized by IES (Illuminating Engineering Society) as a significant advancement in emergency lighting technology and is quickly becoming the product of choice ...
Source: Dental Technology Blog - November 14, 2022 Category: Dentistry Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
SPRING HOUSE, PENNSYLVANIA, November 11, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER program (DISCOVER-1 and DISCOVER-2) evaluating TREMFYA® (guselkumab) in adult patients with active psoriatic arthritis (PsA), which showed that early skin and enthesitis responsesa,b predicted longer-term clinical response,c including disease remission, at week 52.1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active PsA...
Source: Johnson and Johnson - November 11, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
News at a glance: A new antibiotic, COVID-19 in Antarctica, and a Venus mission deferred
CLIMATE SCIENCE
Space station carbon mapper faces demise
An orbiting fridge-size sensor that uses lasers to map forest structure—key to understanding how much carbon trees sequester—is set to plummet to a fiery destruction in the atmosphere in 2023 unless NASA extends its tenure. Researchers and some U.S. Congress members are lobbying the agency to reconsider its plan to jettison the Global Ecosystem Dynamics Investigation (GEDI) instrument from the International Space Station to make way for a Department of Defense sensor. GEDI measures the height of trees and the quality of habitat they provide...
Source: ScienceNOW - November 10, 2022 Category: Science Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life
SPRING HOUSE, PENNSYLVANIA, November 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER-2 study that show early (week 8) clinical improvementsa of most measures (joint and skin disease, enthesitis and dactylitis) in adult patients with active psoriatic arthritis (PsA) treated with TREMFYA® (guselkumab) were associated with meaningful improvements in health-related quality of life (HRQoL) (measured by EQ-5D)b from year one (week 52) through year two (week 100).1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor th...
Source: Johnson and Johnson - November 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
FDA Approves New Fully Liquid Presentation of GSK ’s Rotarix Vaccine to Prevent Gastroenteritis Caused by Rotavirus
New fully liquid formulation of Rotarix removes the need to reconstitute prior to administration, for improved convenience
Clinical data demonstrated non-inferiority of immunogenicity as compared to the lyophilized formulation of Rotarix and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 7, 2022 Category: Drugs & Pharmacology Source Type: news
Red Blood Cells Made to Deliver Antibiotics to Bacteria Red Blood Cells Made to Deliver Antibiotics to Bacteria
A “smart blood” platform delivered antibiotics to E coli without harming normal cells.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 7, 2022 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
Acute Gastroenteritis in US Causes Widespread Disease Acute Gastroenteritis in US Causes Widespread Disease
Acute gastroenteritis is common in the United States and can be spread by asymptomatic virus shedders, report researchers, who recommend hand hygiene and vaccination in order to reduce the spread.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - October 31, 2022 Category: Intensive Care Tags: Infectious Diseases News Source Type: news
Therapeutic use and chronic abuse of CNS stimulants and anabolic drugs - Coli ță D, Coliță CI, Hermann DM, Coliță E, Doeppner TR, Udristoiu I, Popa-Wagner A.
The available evidence suggests that affective disorders, such as depression and anxiety, increase risk for accelerated cognitive decline and late-life dementia in aging individuals. Behavioral neuropsychology studies also showed that cognitive decline is ... (Source: SafetyLit)
Source: SafetyLit - October 31, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Acute Gastroenteritis Outbreaks Common in U.S. Schools, Child Care
MONDAY, Oct. 24, 2022 -- Acute gastroenteritis (AGE) outbreaks frequently occur in schools and child care facilities and most outbreaks spread via person-to-person transmission, according to a study published online Oct. 24 in Pediatrics.
Claire P.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 24, 2022 Category: Pharmaceuticals Source Type: news
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
USDA Proposes Sweeping Changes to Poultry Industry to Cut Food Poisoning
DES MOINES, Iowa — The U.S. Department of Agriculture on Friday proposed sweeping changes in the way chicken and turkey meat is processed that are intended to reduce illnesses from food contamination but could require meat companies to make extensive changes to their operations.
Despite decades of efforts to try and reduce illnesses caused by salmonella in food, more than 1 million people are sickened every year and nearly a fourth of those cases come from turkey and chicken meat.
As it stands, consumers bear much of the responsibility for avoiding illness from raw poultry by handling it carefully in the kitchen&mdas...
Source: TIME: Health - October 14, 2022 Category: Consumer Health News Authors: David Pitt/AP Tags: Uncategorized healthscienceclimate Public Health wire Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Challenging 'Doctor Knows Best'; Vax Controversy in Florida; 6-State E.Coli Outbreak
(MedPage Today) -- Note that some links may require subscriptions.
Merope Mills, an editor for The Guardian, is aggressively fighting the "doctor knows best" mentality after her daughter's preventable death from sepsis. (BBC)
Columbia University... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 10, 2022 Category: American Health Source Type: news
FDA issues warning as E.Coli outbreak linked to Aldi frozen falafel
The Food and Drug Administration (FDA) fears contaminated falafel may still be lurking in people's freezers. Cases have been detected in six states to date. (Source: the Mail online | Health)
Source: the Mail online | Health - October 7, 2022 Category: Consumer Health News Source Type: news
Outbreak of Acute Gastroenteritis Among Rafters and Backpackers in the Backcountry of Grand Canyon National Park, April-June 2022
This report describes an outbreak of acute gastroenteritis in the Grand Canyon National Park backcountry during 2022. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - September 22, 2022 Category: American Health Tags: Food-Related Diseases Foodborne Disease Gastroenteritis MMWR Morbidity & Mortality Weekly Report Norovirus Infection Outbreaks Parks Recreation Source Type: news
